🔗 Share this article

Given that the United States undertakes sweeping adjustments to its vaccine guidelines, one figure has emerged unexpectedly: Høeg, a Danish American sports medicine doctor and public health researcher who rose to prominence by questioning Covid vaccinations during the pandemic and has concentrated on potential deaths after Covid immunization in her brief position at the FDA.

Scheduled Shifts to Pediatric Immunization Program

Agency leaders planned to announce sweeping changes to the pediatric immunization program earlier this month, aligning the US with the Danish vaccine program, it is understood – a significant shift that would place the US at odds with a large portion of the international standard with little proof for improved outcomes. The planned update has been pushed back until the coming year.

Instead of the top vaccines chief, Dr. Høeg is set to present at the gathering. She was recently named temporary leader of the FDA’s CDER, the fifth individual to head the office this year.

Consolidating Power at the FDA

The acting appointment might represent a closer partnership between the drug and vaccine branches as Dr. Høeg and Dr. Prasad consolidate power at the FDA – and it suggests a renewed priority upon reevaluating already-approved vaccines at the FDA.

The new acting director has often pushed for ending specific pediatric immunization guidelines in the US to become more in line with the Danish model, a nation with universal health coverage and a population approximately the size of the state of Wisconsin.

To date public appearances, she has kept her attention on vaccines – traditionally the responsibility of Dr. Prasad, director of the FDA’s CBER – instead of pharmaceutical oversight.

Concerns Over Qualifications

The appointee has little discernible background in pharmaceutical research, oversight or management, which has been standard for previous leaders of the CBER. She has been employed at the FDA as a top consultant to the commissioner and CBER since spring.

“It seems she lacks to have the necessary background” for leading the pharmaceutical oversight division, said a neurologist and psychiatrist. “She’s never run a clinical trial. She lacks experience in managing a major agency. She has no expertise in pharmaceutical oversight.”

Former commissioners of the center would “understand legal statutes and the underlying principles of drug development”, noted a former acting FDA commissioner. “Frankly, she has not acquired the type of experience that previous people who headed CBER have had.”

This division has an immense range of responsibilities at the FDA, the former commissioner stated.

“Many people just zeroes in on the new drug program, but the generic drug division clears thousands of off-brand pharmaceuticals. There is also a biologic copycat branch, non-prescription drug unit and more, and each of these must be managed,” she noted. “The thing you neglect, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a major leadership component to the job, which manages over 5,000 staff members. “It is a huge leadership role, if you do it right,” Woodcock added.

Agency Reaction and Contentious Policies

Regarding inquiries about Høeg’s qualifications and whether this appointment represents more teamwork among regulatory chiefs on immunizations, a spokesperson stated that the “concerns rely on incorrect premises”.

“Her experience aligns with the functions of her job,” the official stated, citing the period Høeg spent counseling the FDA commissioner on “medication safety and approval science, including computerized risk analysis and immunization monitoring”.

As the temporary head, Dr. Høeg takes over the agency head's recently launched expedited review system, a controversial one-day therapy clearance system that reportedly troubled her former heads. “How are these drugs being picked for this expedited pathway? Who takes the calls?” Howard questioned. “There is a lot of confidentiality going on at the FDA right now.”

In general, he said, “the agency looks to be trending towards less stringent regulations of all drugs, with the exception of vaccines.”

Established Past Work on Immunizations

Concerning vaccines, Høeg has a more documented, if concerning, past, some experts have noted. She released a analysis using unconfirmed crowd-sourced reports to assess the incidence of myocarditis following Covid immunization. She advised the state of Florida surgeon general Joseph Ladapo, who allegedly have modified findings to indicate Covid vaccinations are pose a greater threat than they are.

Included in her “wish list” for the incoming administration featured changing regulations for new vaccines and ending “non-essential” vaccines, she remarked after the election on a audio program. At the agency, Dr. Høeg has according to sources floated the idea of barring adolescent males from obtaining COVID-19 vaccines.

“She’s an complete true believer who commences with her beliefs and tailors the evidence to accommodate the science in a very disingenuous, dishonest fashion,” Howard argued.

Consolidating Power and a “Push for Payback”

Dr. Høeg became part of fellow dissenters, {like|